November 2019 – Lung Cancer Awareness Month

This November, the Report Store at Informa Pharma Intelligence is offering 20% off select lung cancer reports to recognize Lung Cancer Awareness Month.

Use lungcancer20 at checkout to take advantage of this special offer.

Related Reports

This Market Spotlight report covers the small cell lung cancer market, comprising key pipeline and marketed drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, licensing and acquisition deals, and drug-specific revenue forecasts.


Mesothelioma is an aggressive and rare form of cancer which develops in the lining of the heart, lungs, or abdomen. Exposure to asbestos is the primary cause of the disease. The inhalation or swallowing of asbestos leads to an accumulation in the lining of the lungs or the abdomen, causing damage to the tissue. This, in turn, leads to damage to the cells’ DNA, and uncontrolled cell growth.

  • New therapies are emerging that harness the immune system to treat cancer, with the PD-1/L1 inhibitor class at the forefront
  • Trial activity within NSCLC is particularly intense, as Opdivo and Keytruda consolidate their leading positions with additional studies, particularly as backbone therapies
  • Clinical successes are driving high patient demand for IO trials, resulting in shorter enrollment durations

Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views on their current application within non-small cell lung cancer (NSCLC), and the potential broader development of immuno-oncology approaches and biomarkers within the indication.